Amgen Inc. (AMGN) FY2025 Annual P&L / Income Statement
2025-01-01 to 2025-12-31
Revenue by Product and Service by Geography
2025-01-01 to 2025-12-31
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2025 Annual P&L / Income Statement
Income statement for 2025-01-01 through 2025-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 36,751,000,000 US dollars
- Cost of sales
- 12,037,000,000 US dollars
- Gross profit (calculated)
- 24,714,000,000 US dollars
- Operating expenses (calculated)
- 15,634,000,000 US dollars
- Operating income
- 9,080,000,000 US dollars
- Other income (expense), net (calculated)
- negative 104,000,000 US dollars
- Total income before income taxes
- 8,976,000,000 US dollars
- Provision for income taxes
- 1,265,000,000 US dollars
- Net income
- 7,711,000,000 US dollars
- Aranesp - UNITED STATES
- 416,000,000 US dollars
- Aranesp - Non-US
- 973,000,000 US dollars
- BLINCYTO - UNITED STATES
- 1,049,000,000 US dollars
- BLINCYTO - Non-US
- 510,000,000 US dollars
- EVENITY - UNITED STATES
- 1,600,000,000 US dollars
- EVENITY - Non-US
- 500,000,000 US dollars
- ENBREL - UNITED STATES
- 2,199,000,000 US dollars
- ENBREL - Non-US
- 27,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 1,340,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- KYPROLIS - UNITED STATES
- 913,000,000 US dollars
- KYPROLIS - Non-US
- 499,000,000 US dollars
- Nplate - UNITED STATES
- 1,027,000,000 US dollars
- Nplate - Non-US
- 497,000,000 US dollars
- Otezla - UNITED STATES
- 1,839,000,000 US dollars
- Otezla - Non-US
- 426,000,000 US dollars
- Other products - UNITED STATES
- 5,437,000,000 US dollars
- Other products - Non-US
- 1,826,000,000 US dollars
- Prolia - UNITED STATES
- 2,978,000,000 US dollars
- Prolia - Non-US
- 1,436,000,000 US dollars
- Repatha - UNITED STATES
- 1,663,000,000 US dollars
- Repatha - Non-US
- 1,353,000,000 US dollars
- TEPEZZA - UNITED STATES
- 1,758,000,000 US dollars
- TEPEZZA - Non-US
- 145,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 1,478,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 604,000,000 US dollars
- Vectibix - Non-US
- 571,000,000 US dollars
- XGEVA - UNITED STATES
- 1,355,000,000 US dollars
- XGEVA - Non-US
- 729,000,000 US dollars
- Other revenues - UNITED STATES
- 763,000,000 US dollars
- Other revenues - Non-US
- 840,000,000 US dollars
- Product sales - UNITED STATES
- 25,656,000,000 US dollars
- Product sales - Non-US
- 9,492,000,000 US dollars
- Research and development
- 7,272,000,000 US dollars
- Selling, general and administrative
- 7,050,000,000 US dollars
- Other
- 1,312,000,000 US dollars
- Revenue before reconciliation (calculated)
- 71,899,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 35,148,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
67.2%
Gross profit / revenue
Operating margin
24.7%
Operating profit / revenue
Cash conversion
129.1%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!